View Filing Data

Print Document View Excel Document

DOCUMENT AND ENTITY INFORMAITON - USD ($)	12 Months Ended
DOCUMENT AND ENTITY INFORMAITON - USD ($)	Dec. 31, 2018	Feb. 21, 2019	Jun. 30, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	DENTSPLY SIRONA INC.
Entity Central Index Key	0000818479
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-K
Trading Symbol	XRAY
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		223,218,138
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 9,706,575,983

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Statement [Abstract]
Net sales	$ 3,986.3	$ 3,993.4	$ 3,745.3
Cost of products sold	1,918.5	1,804.9	1,744.4
Gross profit	2,067.8	2,188.5	2,000.9
Selling, general and administrative expenses	1,719.1	1,674.7	1,523.0
Goodwill impairment	1,085.8	1,650.9	0.0
Restructuring and other costs	221.0	425.2	23.2
Operating (loss) income	(958.1)	(1,562.3)	454.7
Other income and expenses:
Interest expense	37.3	38.3	35.9
Interest income	(2.1)	(2.4)	(2.0)
Other expense (income), net	(34.9)	5.3	(20.1)
(Loss) income before income taxes	(958.4)	(1,603.5)	440.9
Provision (benefit) for income taxes	52.5	(53.2)	9.5
Net (loss) income	(1,010.9)	(1,550.3)	431.4
Less: Net income (loss) attributable to noncontrolling interests	0.1	(0.3)	1.5
Net (loss) income attributable to Dentsply Sirona	$ (1,011.0)	$ (1,550.0)	$ 429.9
Net (loss) income per common share attributable to Dentsply Sirona:
Basic (in dollars per share)	$ (4.51)	$ (6.76)	$ 1.97
Diluted (in dollars per share)	$ (4.51)	$ (6.76)	$ 1.94
Weighted average common shares outstanding:
Basic (in shares)	224.3	229.4	218.0
Diluted (in shares)	224.3	229.4	221.6

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Statement of Comprehensive Income [Abstract]
Net (loss) income	$ (1,010.9)	$ (1,550.3)	$ 431.4
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustments	(180.0)	386.3	(90.5)
Net gain (loss) on derivative financial instruments	29.4	(20.2)	(8.6)
Net unrealized holding gain on available-for-sale securities	(44.3)	44.3	0.0
Pension liability adjustments	7.4	4.6	(13.8)
Total other comprehensive (loss) income	(187.5)	415.0	(112.9)
Total comprehensive (loss) income	(1,198.4)	(1,135.3)	318.5
Less: Comprehensive income attributable to noncontrolling interests	0.3	0.0	0.3
Comprehensive (loss) income attributable to Dentsply Sirona	$ (1,198.7)	$ (1,135.3)	$ 318.2

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Current Assets:
Cash and cash equivalents	$ 309.6	$ 320.6
Accounts and notes receivable-trade, net	701.9	746.2
Inventories, net	598.9	623.1
Prepaid expenses and other current assets	277.6	312.6
Total Current Assets	1,888.0	2,002.5
Property, plant and equipment, net	870.6	876.0
Identifiable intangible assets, net	2,420.3	2,800.7
Goodwill, net	3,431.3	4,539.2
Other noncurrent assets, net	76.8	156.1
Total Assets	8,687.0	10,374.5
Current Liabilities:
Accounts payable	283.9	284.4
Accrued liabilities	578.9	585.8
Income taxes payable	58.1	54.2
Notes payable and current portion of long-term debt	92.4	30.1
Total Current Liabilities	1,013.3	954.5
Long-term debt	1,564.9	1,611.6
Deferred income taxes	552.8	718.0
Other noncurrent liabilities	423.0	462.5
Total Liabilities	3,554.0	3,746.6
Commitments and contingencies
Equity:
Preferred stock, $1.00 par value; 0.25 million shares authorized; no shares issued	0.0	0.0
Common stock, $.01 par value; 400.0 million shares authorized at December 31, 2018 and 2017; 264.5 million shares issued at December 31, 2018 and 2017; 223.0 million and 226.8 million shares outstanding at December 31, 2018 and 2017 respectively	2.6	2.6
Capital in excess of par value	6,522.3	6,543.9
Retained earnings	1,225.9	2,316.2
Accumulated other comprehensive loss	(478.7)	(291.0)
Treasury stock, at cost, 41.5 million and 37.7 million shares at December 31, 2018 and 2017, respectively	(2,151.0)	(1,955.4)
Total Dentsply Sirona Equity	5,121.1	6,616.3
Noncontrolling interests	11.9	11.6
Total Equity	5,133.0	6,627.9
Total Liabilities and Equity	$ 8,687.0	$ 10,374.5

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Preferred stock, par or stated value per share (in dollars per share)	$ 1.00	$ 1.00
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Common stock, par or stated value per share (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	400,000,000	400,000,000
Common stock, shares issued	264,500,000	264,500,000
Common stock, shares outstanding	223,000,000.0	226,800,000
Treasury stock, shares	41,500,000	37,700,000

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($) $ in Millions	Total	Total Dentsply Sirona Equity	Common Stock	Capital in Excess of Par Value	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Treasury Stock	Noncontrolling Interests
Beginning Balance at Dec. 31, 2015	$ 2,339.4	$ 2,338.0	$ 1.6	$ 237.8	$ 3,591.0	$ (594.0)	$ (898.4)	$ 1.4
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	431.4	429.9			429.9			1.5
Other comprehensive (loss) income	(112.9)	(111.7)				(111.7)		(1.2)
Acquisition of noncontrolling interest	(0.4)	(0.1)		(0.1)				(0.3)
Common stock issuance related to Sirona merger	6,266.4	6,256.2	1.0	6,255.2				10.2
Exercise of stock options	37.3	37.3		(10.8)			48.1
Tax benefit from stock options exercised	16.1	16.1		16.1
Stock based compensation expense	41.3	41.3		41.3
Funding of Employee Stock Ownership Plan	6.4	6.4		2.1			4.3
Treasury shares purchased	(815.1)	(815.1)					(815.1)
RSU distributions	(11.7)	(11.7)		(25.5)			13.8
RSU dividends				0.6	(0.6)
Cash dividends	(72.3)	(72.3)			(72.3)
Ending Balance at Dec. 31, 2016	8,125.9	8,114.3	2.6	6,516.7	3,948.0	(705.7)	(1,647.3)	11.6
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(1,550.3)	(1,550.0)			(1,550.0)			(0.3)
Other comprehensive (loss) income	415.0	414.7				414.7		0.3
Exercise of stock options	81.9	81.9		6.9			75.0
Stock based compensation expense	48.0	48.0		48.0
Funding of Employee Stock Ownership Plan	6.6	6.6		3.3			3.3
Treasury shares purchased	(400.3)	(400.3)					(400.3)
RSU distributions	(18.7)	(18.7)		(32.6)			13.9
RSU dividends				0.6	(0.6)
Cash dividends	(80.2)	(80.2)			(80.2)
Ending Balance at Dec. 31, 2017	6,627.9	6,616.3	2.6	6,543.9	2,316.2	(291.0)	(1,955.4)	11.6
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Reclassification on adoption of ASU \| Accounting Standards Update 2016-09				1.0	(1.0)
Net (loss) income	(1,010.9)	(1,011.0)						0.1
Other comprehensive (loss) income	(187.5)	(187.7)				(187.7)		0.2
Exercise of stock options	24.8	24.8		(14.1)			38.9
Stock based compensation expense	21.0	21.0		21.0
Treasury shares purchased	(250.2)	(250.2)					(250.2)
RSU distributions	(13.4)	(13.4)		(29.1)			15.7
RSU dividends				0.6	(0.6)
Cash dividends	(78.1)	(78.1)			(78.1)
Ending Balance at Dec. 31, 2018	5,133.0	5,121.1	$ 2.6	$ 6,522.3	1,225.9	$ (478.7)	$ (2,151.0)	$ 11.9
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Reclassification on adoption of ASU \| Accounting Standards Update 2014-09	(6.0)	(6.0)			(6.0)
Reclassification on adoption of ASU \| Accounting Standards Update 2016-16	(2.7)	(2.7)			(2.7)
Reclassification on adoption of ASU \| Accounting Standards Update 2018-02	$ 8.1	$ 8.1			$ 8.1

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Statement of Stockholders' Equity [Abstract]
Cash dividends (in dollars per share)	$ 0.35	$ 0.35	$ 0.31

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities:
Net (loss) income	$ (1,010.9)	$ (1,550.3)	$ 431.4
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	132.9	127.3	116.6
Amortization of intangible assets	197.9	189.1	155.1
Amortization of deferred financing costs	2.7	2.6	4.5
Goodwill impairment	1,085.8	1,650.9	0.0
Indefinite-lived intangible asset impairment	179.2	346.7	0.0
Deferred income taxes	(62.0)	(143.8)	(110.1)
Stock based compensation expense	21.0	48.0	41.3
Restructuring and other costs - non-cash	22.5	64.7	9.7
Stock option income tax benefit	0.0	0.0	(12.7)
Gain on sale of equity security	(44.1)	0.0	0.0
Other non-cash expense (income)	3.4	9.9	(32.0)
Loss on disposal of property, plant and equipment	4.6	1.6	2.8
Changes in operating assets and liabilities, net of acquisitions:
Accounts and notes receivable-trade, net	23.5	(63.4)	(75.1)
Inventories, net	(19.9)	(62.9)	65.4
Prepaid expenses and other current assets	(27.1)	(75.0)	(32.4)
Other noncurrent assets, net	(12.7)	(3.7)	2.6
Accounts payable	7.1	44.2	7.2
Accrued liabilities	0.3	28.3	(12.2)
Income taxes	12.1	(20.5)	(7.7)
Other noncurrent liabilities	(16.5)	8.2	9.0
Net cash provided by operating activities	499.8	601.9	563.4
Cash flows from investing activities:
Cash paid for acquisitions of businesses and equity investments, net of cash acquired	(130.5)	(145.9)	(341.8)
Proceeds from the sale of businesses	0.0	0.0	6.1
Purchases of short term investments	(3.7)	(2.5)	(6.8)
Capital expenditures	(182.5)	(144.3)	(125.0)
Cash assumed in Sirona merger	0.0	0.0	522.3
Purchase of company owned life insurance policies	0.0	(0.9)	(1.7)
Cash received on derivative contracts	8.0	6.5	20.1
Cash paid on derivative contracts	(2.4)	0.0	(17.1)
Expenditures for identifiable intangible assets	(5.5)	(6.7)	(1.1)
Proceeds from sale of equity security	54.1	0.0	0.0
Proceeds from sale of property, plant and equipment	9.2	7.4	5.0
Net cash (used in) provided by investing activities	(253.3)	(286.4)	60.0
Cash flows from financing activities:
Proceeds from long-term borrowings, net of deferred financing costs	0.1	3.1	1,220.6
Payments on long-term borrowings	(9.4)	(16.7)	(877.5)
Increase (decrease) in short-term borrowings	60.4	10.2	(44.1)
Proceeds from exercise of stock options	27.9	82.3	41.0
Excess tax benefits from stock based compensation	0.0	0.0	12.7
Cash paid for acquisition of noncontrolling interests of consolidated subsidiaries	0.0	0.0	(0.4)
Cash paid for treasury stock	(250.2)	(401.4)	(813.9)
Cash dividends paid	(78.6)	(78.3)	(64.6)
Net cash used in financing activities	(249.8)	(400.8)	(526.2)
Effect of exchange rate changes on cash and cash equivalents	(7.7)	22.0	2.1
Net (decrease) increase in cash and cash equivalents	(11.0)	(63.3)	99.3
Cash and cash equivalents at beginning of period	320.6	383.9	284.6
Cash and cash equivalents at end of period	309.6	320.6	383.9
Schedule of non-cash investing activities:
Merger financed by common stock	0.0	0.0	6,256.2
Supplemental disclosures of cash flow information:
Interest paid, net of amounts capitalized	35.1	37.0	36.7
Income taxes paid	$ 104.7	$ 122.7	$ 112.3

SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

Description of Business

DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the “Company”), is the world’s largest manufacturer of professional dental products and technologies, with a 130-year history of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable healthcare products under a strong portfolio of world class brands. The Company’s principal product categories are dental consumable products, dental equipment, healthcare consumable products and dental technologies. The Company distributes its products in over 120 countries under some of the most well established brand names in the industry.

On February 29, 2016, DENTSPLY International Inc. merged with Sirona Dental Systems, Inc. (“Sirona”) to form DENTSPLY SIRONA Inc. (the “Merger”). The Consolidated Statements of Operations for the year ended December 31, 2016 include the results of operations for Sirona for the period February 29, 2016 to December 31, 2016.

Unless otherwise stated herein, reference throughout this Form 10-K to “Dentsply Sirona”, or the “Company” refers to financial information and transactions of DENTSPLY International Inc. (“DENTSPLY”) prior to February 29, 2016 and to financial information and transactions of DENTSPLY SIRONA Inc., thereafter.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates, and such differences may be material to the consolidated financial statements.

Principles of Consolidation

The consolidated financial statements include the accounts of the Company. All significant intercompany accounts and transactions are eliminated in consolidation.

Investments in non-consolidated affiliates (20-50 percent owned companies, joint ventures and partnerships as well as less than 20 percent ownership positions where the Company maintains significant influence over the subsidiary) are accounted for using the equity method.

Cash and Cash Equivalents

Cash and cash equivalents include deposits with banks as well as highly liquid time deposits with maturities at the date of purchase of ninety days or less.

Short-term Investments

Short-term investments are highly liquid time deposits with original maturities at the date of purchase greater than ninety days and with remaining maturities of one year or less.

Accounts and Notes Receivable-Trade

The Company sells dental and certain medical products and equipment through a worldwide network of distributors and directly to end users. For customers on credit terms, the Company performs ongoing credit evaluation of those customers’ financial condition and generally does not require collateral from them. The Company establishes allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. The Company records a provision for doubtful accounts, which is included in Selling, general and administrative expenses in the Consolidated Statements of Operations.

Accounts receivable – trade is stated net of these allowances that were $24.5 million and $22.4 million at December 31, 2018 and 2017, respectively. For the years ended December 31, 2018 and 2017, the Company wrote-off $2.6 million and $4.8 million, respectively, of accounts receivable that were previously reserved. The Company increased the provision for doubtful accounts by $6.0 million and $6.6 million during 2018 and 2017, respectively.

Inventories

Inventories are stated at the lower of cost and net realizable value. At December 31, 2018 and 2017, the cost of $9.0 million and $12.4 million, respectively, of inventories was determined by the last-in, first-out (“LIFO”) method. The cost of remaining inventories was determined by the first-in, first-out (“FIFO”) or average cost methods.

If the FIFO method had been used to determine the cost of LIFO inventories, the amounts at which net inventories are stated would be higher than reported at December 31, 2018 and 2017 by $10.2 million and $10.6 million, respectively.

The Company establishes reserves for inventory estimated to be obsolete or unmarketable equal to the difference between the cost of inventory and estimated market value based upon assumptions about future demand and market conditions.

Valuation of Goodwill and Other Long-Lived Assets

Assessment of the potential impairment of goodwill and other long-lived assets is an integral part of the Company’s normal ongoing review of operations. Testing for potential impairment of these assets is significantly dependent on assumptions and reflects management’s best estimates at a particular point in time. The dynamic economic environments in which the Company’s businesses operate and key economic and business assumptions with respect to projected selling prices, increased competition and introductions of new technologies can significantly affect the outcome of impairment tests. Estimates based on these assumptions may differ significantly from actual results. Changes in factors and assumptions used in assessing potential impairments can have a significant impact on the existence and magnitude of impairments, as well as the time at which such impairments are recognized. If there are unfavorable changes in these assumptions, future cash flows, a key variable in assessing the impairment of these assets, may decrease and as a result the Company may be required to recognize impairment charges. Future changes in the environment and the economic outlook for the assets being evaluated could also result in additional impairment charges being recognized. The following information outlines the Company’s significant accounting policies on long-lived assets by type.

Goodwill

Goodwill is the excess of the purchase price over the fair value of identifiable net assets acquired and liabilities assumed in a business combination. Goodwill is not amortized. The Company conducts an annual impairment test during the Company’s second quarter, or when indications of potential impairment exist. The Company monitors for the existence of potential impairment throughout the year. This impairment assessment includes an evaluation of various reporting units, which is an operating segment or one reporting level below the operating segment. The Company performs impairment tests using a fair value approach which compares the fair value of each reporting unit to its carrying amount to determine if there is potential goodwill impairment. If impairment is identified on goodwill, the resulting charge is determined by recalculating goodwill through a hypothetical purchase price allocation of the fair value and reducing the current carrying value to the extent it exceeds the recalculated goodwill.

The Company’s fair value approach involves using a discounted cash flow model with market-based support as its valuation technique to measure the fair value for its reporting units. The discounted cash flow model uses five- to ten- year forecasted cash flows plus a terminal value based on a multiple of earnings or by capitalizing the last period’s cash flows using a perpetual growth rate. In addition, the Company applies gross profit and operating expense assumptions consistent with its historical trends. The total cash flows were discounted based on market participant data, which included the Company’s weighted-average cost of capital. The Company considered the current market conditions when determining its assumptions. Lastly, the Company reconciled the aggregate fair values of its reporting units to its market capitalization, which included a reasonable control premium based on market conditions. Additional information related to the testing for goodwill impairment is provided in Note 9 Goodwill and Intangible Assets.

Indefinite-Lived Intangible Assets

Indefinite-lived intangible assets consist of tradenames and trademarks and are not subject to amortization. Valuations of identifiable intangibles assets acquired are based on information and assumptions available at the time of acquisition, using income and market model approaches to determine fair value. In-process research and development assets are not subject to amortization until the product associated with the research and development is substantially complete and is a viable product. At that time, the useful life to amortize the intangible asset is determined by identifying the period in which substantially all the cash flows are expected to be generated and the asset is moved to definite-lived.

These assets are reviewed for impairment annually during the Company's second quarter, or whenever events or circumstances suggest that the carrying amount of the asset may not be recoverable. The Company performs impairment tests using an income approach, more specifically a relief from royalty method. In the development of the forecasted cash flows, the Company applies significant management judgment to determine key assumptions, including revenue growth, royalty rates and discount rates assumptions. Royalty rates used are consistent with those assumed for the original purchase accounting valuation. Other assumptions are consistent with those applied to goodwill impairment testing. If the carrying value exceeds the fair value, an impairment loss in the amount equal to the excess is recognized.

Identifiable Definite-Lived Intangible Assets

Identifiable definite-lived intangible assets, which primarily consist of patents, tradenames, trademarks, brand names, non-compete agreements and licensing agreements, are amortized on a straight-line basis over their estimated useful lives. The useful life is the period over which the asset is expected to contribute to the future cash flows of the Company. The Company uses the following guidance to determine the useful life of certain intangible assets:


Intangible Asset Type						Life

Patents						Up to date patent expires
Tradenames and trademarks						Up to 20 years
Licensing agreements						Up to 20 years
Customer relationships						Up to 15 years

When the expected life is not known, the Company will estimate the useful life based on similar asset or asset groups, any legal, regulatory, or contractual provision that limits the useful life, the effect of economic factors, including obsolescence, demand, competition, and the level of maintenance expenditures required to obtain the expected future economic benefit from the asset. Valuations of identifiable intangibles assets acquired are based on information and assumptions available at the time of acquisition, using income and market model approaches to determine fair value.

These assets are reviewed for impairment whenever events or circumstances suggest that the carrying amount of the asset may not be recoverable. The Company closely monitors all intangible assets including those related to new and existing technologies for indicators of impairment as these assets have more risk of becoming impaired. Impairment is based upon an initial evaluation of the identifiable undiscounted cash flows. If the initial evaluation identifies a potential impairment, a fair value of the asset is determined by using a discounted cash flows valuation. If impaired, the resulting charge reflects the excess of the asset’s carrying cost over its fair value.

Property, Plant and Equipment

Property, plant and equipment are stated at cost, with the exception of assets acquired through acquisitions, which are recorded at fair value, net of accumulated depreciation. Except for leasehold improvements, depreciation for financial reporting purposes is computed by the straight-line method over the following estimated useful lives: generally 40 years for buildings and 4 to 15 years for machinery and equipment. The cost of leasehold improvements is amortized over the shorter of the estimated useful life or the term of the lease. Maintenance and repairs are expensed as incurred to the statements of operations; replacements and major improvements are capitalized. These asset groups are reviewed for impairment whenever events or circumstances suggest that the carrying amount of the asset group may not be recoverable. Impairment is based upon an evaluation of the identifiable undiscounted cash flows. If impaired, the resulting charge reflects the excess of the asset group’s carrying cost over its fair value.

Derivative Financial Instruments

The Company records all derivative instruments in the consolidated balance sheet at fair value and changes in fair value are recorded each period in the consolidated statements of operations or accumulated other comprehensive income (“AOCI”). The Company classifies derivative assets and liabilities as current when the remaining term of the derivative contract is one year or less. The Company has elected to classify the cash flow from derivative instruments in the same category as the cash flows from the items being hedged. Should the Company enter into a derivative instrument that included an other-than-insignificant financing element then all cash flows will be classified as financing activities in the Consolidated Statements of Cash Flows as required by US GAAP.

The Company employs derivative financial instruments to hedge certain anticipated transactions, firm commitments, and assets and liabilities denominated in foreign currencies. Additionally, the Company utilizes interest rate swaps to convert floating rate debt to fixed rate.

Pension and Other Postemployment Benefits

Some of the employees of the Company and its subsidiaries are covered by government or Company-sponsored defined benefit plans. Many of the employees have available to them defined contribution plans. Additionally, certain union and salaried employee groups in the United States are covered by postemployment healthcare plans. Costs for Company-sponsored defined benefit and postemployment benefit plans are based on expected return on plan assets, discount rates, employee compensation increase rates and health care cost trends. Expected return on plan assets, discount rates and health care cost trend assumptions are particularly important when determining the Company’s benefit obligations and net periodic benefit costs associated with postemployment benefits. Changes in these assumptions can impact the Company’s earnings before income taxes. In determining the cost of postemployment benefits, certain assumptions are established annually to reflect market conditions and plan experience to appropriately reflect the expected costs as actuarially determined. These assumptions include medical inflation trend rates, discount rates, employee turnover and mortality rates. The Company predominantly uses liability durations in establishing its discount rates, which are observed from indices of high-grade corporate bond yields in the respective economic regions of the plans. The expected return on plan assets is the weighted average long-term expected return based upon asset allocations and historic average returns for the markets where the assets are invested, principally in foreign locations. The Company reports the funded status of its defined benefit pension and other postemployment benefit plans on its consolidated balance sheets as a net liability or asset. Additional information related to the impact of changes in these assumptions is provided in Note 15, Benefit Plans.

Accruals for Self-Insured Losses

The Company maintains insurance for certain risks, including workers’ compensation, general liability, product liability and vehicle liability, and is self-insured for employee related healthcare benefits. The Company accrues for the expected costs associated with these risks by considering historical claims experience, demographic factors, severity factors and other relevant information. Costs are recognized in the period the claim is incurred, and the financial statement accruals include an estimate of claims incurred but not yet reported. The Company has stop-loss coverage to limit its exposure to any significant exposure on a per claim basis.

Litigation

The Company and its subsidiaries are from time to time parties to lawsuits arising out of their respective operations. The Company records liabilities when a loss is probable and can be reasonably estimated. These estimates are typically in the form of ranges, and the Company records the liabilities at the low point of the ranges, when no other point within the ranges are a better estimate of the probable loss. The ranges established by management are based on analysis made by internal and external legal counsel who considers information known at the time. If the Company determines a liability to be only reasonably possible, it considers the same information to estimate the possible exposure and discloses any material potential liability. These loss contingencies are monitored regularly for a change in fact or circumstance that would require an accrual adjustment. The Company believes it has estimated liabilities for probable losses appropriately in the past; however, the unpredictability of litigation and court decisions could cause a liability to be incurred in excess of estimates. Legal costs related to these lawsuits are expensed as incurred.

Foreign Currency Translation

The functional currency for foreign operations, except for those in highly inflationary economies, generally has been determined to be the local currency.

Assets and liabilities of foreign subsidiaries are translated at foreign exchange rates on the balance sheet date; revenue and expenses are translated at the average year-to-date foreign exchange rates. The effects of these translation adjustments are reported in Equity within AOCI in the Consolidated Balance Sheets. During the year ended December 31, 2018, the Company had gains of $14.9 million on its loans designated as hedges of net investments and translation losses of $200.1 million. During the year ended December 31, 2017, the Company had losses of $48.5 million on its loans designated as hedges of net investments and translation gains of $434.5 million.

Foreign exchange gains and losses arising from transactions denominated in a currency other than the functional currency of the entity involved and remeasurement adjustments in countries with highly inflationary economies are included in income. Net foreign exchange transaction losses of $5.8 million and $1.7 million in 2018 and 2017, respectively, and gain of $10.2 million in 2016 are included in Other expense (income), net in the Consolidated Statements of Operations.

Revenue Recognition

Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied; generally this occurs with the transfer of risk and/or control of Dental and Healthcare Consumables products ("consumable" products), Dental Technology products ("technology" products), or Dental Equipment products ("equipment" products). Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods or providing services. Sales, value add, and other taxes collected concurrent with revenue-producing activities are excluded from revenue. Incidental items that are immaterial in the context of the contract are recognized as expense.

For most of consumables, technologies, and equipment, the Company transfers control and recognizes a sale when products are shipped from the Company's manufacturing facility or warehouse to the customer (distributors and direct to dentists). For contracts with customers that contain destination shipping terms, revenue is not recognized until risk has transferred and the goods are delivered to the agreed upon destination. The amount of consideration received and revenue recognized varies with changes in marketing incentives (e.g. discounts, rebates, free goods) and returns offered to customers and their customers. When the Company gives customers the right to return eligible products and receive credit, returns are estimated based on an analysis of historical experience. However, returns of products, excluding warranty related returns, are infrequent and insignificant. The Company adjusts the estimate of revenue at the earlier of when the most likely amount of consideration can be estimated, the amount expected to be received changes, or when the consideration becomes fixed. Consideration received from customers in advance of revenue recognition is classified as deferred revenue.

Depending on the terms of the arrangement, the Company may also defer the recognition of a portion of the consideration received when performance obligations are not yet satisfied (e.g., free extended maintenance/service contracts, software and licenses, customer loyalty points and coupon programs). The Company uses an observable price, typically average selling price, to determine the stand-alone selling price for separate performance obligations. The Company determines the stand-alone selling price, based on Company geographic sales locations' database of pricing and discounting practices for the specific product or service when sold separately, and utilizes this data to arrive at average selling prices by product. Revenue is then allocated proportionately, based on the determined stand-alone selling price, to the unsatisfied performance obligation, which is deferred until satisfied. At December 31, 2018, the Company had $29.3 million of deferred revenue recorded in Accrued liabilities in the Consolidated Balance Sheets. The Company expects to recognize significantly all of the deferred revenue within the next twelve months.

The Company has elected to account for shipping and handling activities as a fulfillment cost within the cost of products sold, and records shipping and handling costs collected from customers in net sales. The Company has adopted two practical expedients: the “right to invoice” practical expedient, which allows us to recognize revenue in the amount of the invoice when it corresponds directly with the value of performance completed to date; and relief from considering the existence of a significant financing component when the payment for the good or service is expected to be one year or less.

The Company offers discounts to its customers and distributors if certain conditions are met. Discounts are primarily based on the volume of products purchased or targeted to be purchased by the customer or distributor. Discounts are deducted from revenue at the time of sale or when the discount is offered, whichever is later. The Company estimates volume discounts based on the individual customer’s or distributor's historical and estimated future product purchases.

Certain of the Company’s customers are offered cash rebates based on targeted sales increases. The Company estimates rebates based on the forecasted performance of a customer and their expected level of achievement within the rebate programs. In accounting for these rebate programs, the Company records an accrual and reduces net sales ratably as sales occur over the rebate period. The Company updates the accruals for these rebate programs as actual results and updated forecasts impact the estimated achievement for customers within the rebate programs.

A portion of the Company’s net sales is comprised of sales of precious metals generated through its precious metal dental alloy product offerings. As the precious metal content of the Company’s sales is largely a pass-through to customers, the Company uses its cost of precious metal purchased as a proxy for the precious metal content of sales, as the precious metal content of sales is not separately tracked and invoiced to customers. The Company believes that it is reasonable to use the cost of precious metal content purchased in this manner since precious metal alloy sale prices are typically adjusted when the prices of underlying precious metals change.

Cost of Products Sold

Cost of products sold represents costs directly related to the manufacture and distribution of the Company’s products. Primary costs include raw materials, packaging, direct labor, overhead, shipping and handling, warehousing and the depreciation of manufacturing, warehousing and distribution facilities. Overhead and related expenses include salaries, wages, employee benefits, utilities, lease costs, maintenance and property taxes.

Warranties

The Company provides warranties on certain equipment products. Estimated warranty costs are accrued when sales are made to customers. Estimates for warranty costs are based primarily on historical warranty claim experience. Warranty costs are included in Cost of products sold in the Consolidated Statements of Operations. The following table presents the Company’s warranty expense and warranty accrual at December 31:


	December 31,
(in millions)	2018		2017		2016

Warranty Expense	$	23.7	$	25.7	$	25.2
Warranty Accrual	13.0		11.8		11.2

Selling, General and Administrative Expenses

Selling, general and administrative expenses represent costs incurred in generating revenues and in managing the business of the Company. Such costs include advertising and other marketing expenses, salaries, employee benefits, incentive compensation, research and development, travel, office expenses, lease costs, amortization of capitalized software and depreciation of administrative facilities. Advertising cost are expensed as incurred.

Research and Development Costs

Research and development (“R&D”) costs relate primarily to internal costs for salaries and direct overhead expenses. In addition, the Company contracts with outside vendors to conduct R&D activities. All such R&D costs are charged to expense when incurred. The Company capitalizes the costs of equipment that have general R&D uses and expenses such equipment that is solely for specific R&D projects. The depreciation expense related to this capitalized equipment is included in the Company’s R&D costs. Software development costs incurred prior to the attainment of technological feasibility are considered R&D and are expensed as incurred. Once technological feasibility is established, software development costs are capitalized until the product is available for general release to customers. Amortization of these costs are included in Cost of products sold over the estimated life of the products. R&D costs are included in Selling, general and administrative expenses in the Consolidated Statements of Operations and amounted to $160.5 million, $151.7 million and $128.5 million for 2018, 2017 and 2016, respectively.

Stock Compensation

The Company recognizes the compensation cost relating to stock-based payment transactions in the financial statements. The cost of stock-based payment transactions is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense over the employee’s requisite service period (generally the vesting period of the equity awards). The compensation cost is only recognized for the portion of the awards that are expected to vest.

Income Taxes

The Company’s tax expense includes U.S. and international income taxes plus the provision for U.S. taxes on undistributed earnings of international subsidiaries not deemed to be permanently invested. Tax credits and other incentives reduce tax expense in the year the credits are claimed. Certain items of income and expense are not reported in tax returns and financial statements in the same year. The tax effect of such temporary differences is reported as deferred income taxes. Deferred tax assets are recognized if it is more likely than not that the assets will be realized in future years. The Company establishes a valuation allowance for deferred tax assets for which realization is not likely.

The Company applies a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Company recognizes in the financial statements, tax benefits from an uncertain tax position only if is more likely than not that the position will be sustained upon examination by the taxing authorities based on the technical merits of the position.

See Note 14, Income Taxes, for further information relating to the enactment of the Tax Cuts and Jobs Act (the "Act" or "U.S. tax reform").

Earnings Per Share

Basic earnings per share are calculated by dividing net earnings by the weighted average number of shares outstanding for the period. Diluted earnings per share is calculated by dividing net earnings by the weighted average number of shares outstanding for the period, adjusted for the effect of an assumed exercise of all dilutive options outstanding at the end of the period.

Business Acquisitions

The Company acquires businesses as well as partial interests in businesses. Acquired businesses are accounted for using the acquisition method of accounting which requires the Company to record assets acquired and liabilities assumed at their respective fair values with the excess of the purchase price over estimated fair values recorded as goodwill. The assumptions made in determining the fair value of acquired assets and assumed liabilities as well as asset lives can materially impact the results of operations.

The Company obtains information during due diligence and through other sources to establish respective fair values. Examples of factors and information that the Company uses to determine the fair values include: tangible and intangible asset evaluations and appraisals; evaluations of existing contingencies and liabilities and product line information. If the initial valuation for an acquisition is incomplete by the end of the quarter in which the acquisition occurred, the Company will record a provisional estimate in the financial statements. The provisional estimate will be finalized as soon as information becomes available, but will only occur up to one year from the acquisition date.

Noncontrolling Interests

The Company reports noncontrolling interest (“NCI”) in a subsidiary as a separate component of Equity in the Consolidated Balance Sheets. Additionally, the Company reports the portion of net income (loss) and comprehensive income (loss) attributed to the Company and NCI separately in the Consolidated Statements of Operations. The Company also includes a separate column for NCI in the Consolidated Statements of Changes in Equity.

Segment Reporting

The Company has numerous operating businesses covering a wide range of products and geographic regions, primarily serving the professional dental market and to a lesser extent the consumable medical device market. Professional dental products and equipment represented approximately 91%, 92% and 92% of sales for the years ended 2018, 2017 and 2016, respectively. The Company has two reportable segments and a description of the activities within these segments is included in Note 5, Segment and Geographic Information.

Fair Value Measurement

Recurring Basis

The Company records certain financial assets and liabilities at fair value in accordance with the accounting guidance, which defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The accounting guidance establishes a hierarchical disclosure framework associated with the level of pricing observability utilized in measuring financial instruments at fair value. The three broad levels defined by the fair value hierarchy are as follows:

Level 1 - Quoted prices are available in active markets for identical assets or liabilities as of the reported date.

Level 2 - Pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable reported date. The nature of these financial instruments include derivative instruments whose fair value have been derived using a model where inputs to the model are directly observable in the market or can be derived principally from, or corroborated by observable market data.

Level 3 - Instruments that have little to no pricing observability as of the reported date. These financial instruments do not have two-way markets and are measured using management’s best estimate of fair value, where the inputs into the determination of fair value require significant management judgment or estimation.

The degree of judgment utilized in measuring the fair value of certain financial assets and liabilities generally correlates to the level of pricing observability. Pricing observability is impacted by a number of factors, including the type of financial instrument. Financial assets and liabilities with readily available active quoted prices or for which fair value can be measured from actively quoted prices generally will have a higher degree of pricing observability and a lesser degree of judgment utilized in measuring fair value. Conversely, financial assets and liabilities rarely traded or not quoted will generally have less, or no pricing observability and a higher degree of judgment utilized in measuring fair value.

The Company primarily applies the market approach for recurring fair value measurements and endeavors to utilize the best available information. Accordingly, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Additionally, the Company considers its credit risks and its counterparties’ credit risks when determining the fair values of its financial assets and liabilities. The Company has presented the required disclosures in Note 18, Fair Value Measurement.

Non-Recurring Basis

When events or circumstances require an asset or liability to be fair valued that otherwise is generally recorded based on another valuation method, such as, net realizable value, the Company will utilize the valuation techniques described above.

Recently Adopted Accounting Pronouncements

Effective January 1, 2018, the Company adopted Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers”, as amended (Topic 606, commonly referred to as ASC 606) to all contracts using the modified retrospective method. The Company recognized the cumulative effect of initially applying the new revenue standard as an adjustment to the opening balance of retained earnings. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods.

Most of the Company’s revenue continues to be recognized when products are shipped from manufacturing facilities. For certain customer and dealer incentive programs, such as coupons, customer loyalty and free goods, the Company recognizes the proportionate revenue and cost of product when the incentives are shipped or awarded. Prior to adoption of ASC 606, costs for these types of programs were recognized when triggering events occurred. For contracts with customers where performance occurs over time, such as software sales, the Company recognizes revenue ratably over the performance period.

The new revenue standard also provided additional guidance that resulted in reclassifications to or from Net sales, Cost of products sold, Selling, general and administrative expenses, and the resultant change in Provision (benefit) for income taxes.

The cumulative effect of the changes made in the Consolidated Balance Sheets at December 31, 2017 for the adoption of ASC 606, was as follows:


Consolidated Balance Sheets Item
(in millions)	December 31, 2017 As Reported Balance		Adoption of ASC 606		January 1, 2018 Revised Balance

Assets
Accounts and notes receivable-trade, net	$	746.2	$	0.2	$	746.4
Inventory, net	623.1		(0.3)		622.8
Prepaid expense and other current assets, net	312.6		1.9		314.5

Liabilities and Equity
Accrued liabilities	$	585.8	$	9.9	$	595.7
Income taxes payable	54.2		(2.1)		52.1
Retained earnings	2,316.2		(6.0)		2,310.2

The impact of adopting the new revenue recognition standard on the Company's Consolidated Statements of Operations and Consolidated Balance Sheets was as follows:


Consolidated Statements of Operations Item	December 31, 2018
(in millions)	As Reported Balance		Balances Without Adoption of ASC 606		Effect of Change Increase/(Decrease)

Net sales	$	3,986.3	$	3,986.8	$	(0.5)

Selling, general and administrative expenses	1,719.1		1,719.0		0.1
Provision (benefit) for income taxes	52.5		52.6		(0.1)
Net (loss) income attributable to Dentsply Sirona	(1,011.0)		(1,010.5)		(0.5)


Consolidated Balance Sheets Item	December 31, 2018
(in millions)	As Reported Balance		Balances Without Adoption of ASC 606		Effect of Change Increase/(Decrease)

Assets
Accounts and notes receivables-trade, net	$	701.9	$	701.8	$	0.1
Inventories, net	598.9		599.2		(0.3)
Prepaid expenses and other current assets	277.6		276.2		1.4

Liabilities and Equity
Accrued liabilities	$	578.9	$	568.9	$	10.0
Income taxes payable	58.1		60.4		(2.3)
Retained earnings	1,225.9		1,232.4		(6.5)

Effective January 1, 2018, the Company adopted ASU No. 2016-16, “Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory.” This accounting standard seeks to improve the accounting for the income tax consequences of intra-entity transfers of assets other than inventory. Previously, US GAAP prohibited the recognition of current and deferred income taxes for an intra-entity asset transfer until the asset has been sold to a third party, which is an exception to the principle of comprehensive recognition of current and deferred income taxes in US GAAP. ASU No. 2016-16 eliminates this exception. The Company adopted this accounting standard using the modified retrospective method with a cumulative-effect adjustment directly to retained earnings. Upon adoption, the Company made the following reclassification:


Consolidated Balance Sheets Item
(in millions)	December 31, 2017 As Reported Balance		Adoption of ASU 2016-16 Increase/(Decrease)		January 1, 2018 Revised Balance

Assets
Prepaid expenses and other current assets	$	312.6	$	(5.6)	$	307.0
Other noncurrent assets, net	156.1		(73.1)		83.0

Liabilities and Equity
Deferred income taxes	$	718.0	$	(76.0)	$	642.0
Retained earnings	2,316.2		(2.7)		2,313.5

In March 2017, the FASB issued ASU No. 2017-07, “Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost.” This accounting standard is primarily intended to improve the presentation of net periodic pension cost and net periodic postretirement benefit cost. The amendments in this update require an employer to report the service cost component of net periodic benefit cost in operating income, while the interest cost, amortization, return on assets and any settlement or curtailment expense will be reported below operating income. More specifically, the service cost will be reported in the same line item as other compensation costs arising from the services rendered by the pertinent employee during the period. The amendments in this update are required for annual and interim periods beginning after December 15, 2017, and should be applied retrospectively for the presentation of the components of net periodic benefit cost and net periodic postretirement benefit cost in the income statement. The amendment allows a practical expedient that permits an employer to use the amounts disclosed in its pension and other postretirement benefit plan note for the prior comparative periods as the estimation basis for applying the retrospective presentation requirements. The Company adopted this accounting standard on January 1, 2018, and applied the practical expedient upon adoption. The impact of adopting this standard, by financial statement line item, for the year ended December 31, 2017 and 2016 is reflected below:


Consolidated Statements of Operations Item
(in millions)	December 31, 2017 As Reported Balance		Adoption of ASU 2017-07 Increase/(Decrease)		December 31, 2017 Revised Balance

Cost of products sold	$	1,804.9	$	(3.9)	$	1,801.0
Gross profit	2,188.5		3.9		2,192.4
Selling, general and administrative expense	1,674.7		(5.3)		1,669.4
Operating (loss) income	(1,562.3)		9.2		(1,553.1)
Other expense (income), net	5.3		9.2		14.5


Consolidated Statements of Operations Item
(in millions)	December 31, 2016 As Reported Balance		Adoption of ASU 2017-07 Increase/(Decrease)		December 31, 2016 Revised Balance

Cost of products sold	$	1,744.4	$	(3.7)	$	1,740.7
Gross profit	2,000.9		3.7		2,004.6
Selling, general and administrative expense	1,523.0		(5.3)		1,517.7
Operating (loss) income	454.7		9.0		463.7
Other expense (income), net	(20.1)		9.0		(11.1)

In February 2018, the FASB issued ASU No. 2018-02, “Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income.” This newly issued accounting standard allows for a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from tax rate changes due to the Tax Cuts and Jobs Act. The amendments in this update are required for annual and interim periods beginning after December 15, 2018. This standard also requires the Company to disclose its accounting policy for releasing income tax effects from accumulated other comprehensive income. In general, the Company applies the individual item approach. As permitted by the accounting standard, the Company early adopted this accounting standard on January 1, 2018. As a result of the adoption, the Company elected to reclassify the income tax effects from AOCI to Retained earnings and reclassified $8.1 million.

Accounting Standards Not Yet Adopted

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) with subsequent amendments (collectively, “Topic 842”). The Company will adopt the new leasing standard in the first quarter of 2019 using the modified retrospective approach transition method through a cumulative-effect adjustment at the beginning of the period of adoption. Results for reporting periods beginning after January 1, 2019 will be presented under ASC 842, while prior periods are not adjusted and continue to be reported in accordance with historic accounting under ASC 840. The Company expects to elect the package of practical expedients permitted under the transition guidance within the standard, which eliminates the reassessment of past leases, classification and initial direct costs. The Company does not expect to elect to adopt the hindsight practical expedient. The Company expects that adoption of the new leasing standard will result in recognition of material right-of-use asset and liabilities on the consolidated balance sheets for its operating lease commitments with terms greater than twelve months.

In August 2017, the FASB issued ASU No. 2017-12, “Derivatives and Hedging.” This newly issued accounting standard improves the financial reporting and disclosure of hedging relationships to better portray the economic results of an entity’s risk management activities in its financial statements. The amendments in this update make improvements to simplify the application of the hedge accounting guidance in current US GAAP based on the feedback received from preparers, auditors, users and other stakeholders. More specifically, this update expands and refines hedge accounting for both nonfinancial and financial risk components and align the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. The amendments in this update are required for annual and interim periods beginning after December 15, 2018. Early adoption is permitted. The effect of adoption should be reflected as of the beginning of the fiscal year of adoption. For cash flow and net investment hedges existing at the date of adoption, an entity should apply a cumulative-effect adjustment related to eliminating the separate measurement of ineffectiveness to accumulated other comprehensive income with a corresponding adjustment to the opening balance of retained earnings as of the beginning of the fiscal year that an entity adopts the amendments in this update. The amended presentation and disclosure guidance is required only prospectively. The Company will adopt this accounting standard for the quarter ended March 31, 2019. The adoption of this standard will not materially impact the statements of operations, financial position, cash flows and disclosures.

In August 2018, the FASB issued ASU No. 2018-14 "Compensation - Retirement Benefits - Defined Benefit Plans - General (Subtopic 715-20): Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans." This newly issued accounting standard changes disclosure requirements for defined benefit plans, including removal and modification of existing disclosures. The amendments in this standard are required for fiscal years ending after December 15, 2020. Early adoption is permitted. The amendments should be applied on a retrospective basis for all periods presented. The Company is currently assessing the impact that this standard will have on its financial position, results of operations, cash flows and disclosures.

EARNINGS PER COMMON SHARE

12 Months Ended

Dec. 31, 2018

Earnings Per Share [Abstract]

EARNINGS PER COMMON SHARE

The following table sets forth the computation of basic and diluted (loss) earnings per common share for the year ended December 31:


Basic Earnings Per Common Share Computation
(in millions, except per share amounts)	2018		2017		2016

Net (loss) income attributable to Dentsply Sirona	$	(1,011.0)	$	(1,550.0)	$	429.9

Weighted average common shares outstanding	224.3		229.4		218.0

(Loss) earnings per common share - basic	$	(4.51)	$	(6.76)	$	1.97

Diluted Earnings Per Common Share Computation
(in millions, except per share amounts)	2018		2017		2016

Net (loss) income attributable to Dentsply Sirona	$	(1,011.0)	$	(1,550.0)	$	429.9

Weighted average common shares outstanding	224.3		229.4		218.0
Incremental weighted average shares from assumed exercise of dilutive options from stock-based compensation awards	—		—		3.6
Total weighted average diluted shares outstanding	224.3		229.4		221.6

(Loss) earnings per common share - diluted	$	(4.51)	$	(6.76)	$	1.94

The calculation of weighted average diluted shares outstanding excludes stock options and restricted stock units (“RSUs”) of 5.1 million, 4.3 million and 0.6 million shares of common stock that were outstanding during the years ended December 31, 2018, 2017 and 2016, respectively, were excluded from the computation of diluted earnings per common share since their effect would be antidilutive.

COMPREHENSIVE INCOME

12 Months Ended

Dec. 31, 2018

Other Comprehensive Income (Loss), Net of Tax [Abstract]

COMPREHENSIVE INCOME

AOCI includes foreign currency translation adjustments related to the Company’s foreign subsidiaries, net of the related changes in certain financial instruments hedging these foreign currency investments. In addition, changes in the Company’s fair value of certain derivative financial instruments, pension liability adjustments and prior service costs, net are recorded in AOCI. These changes are recorded in AOCI net of any related tax adjustments. For the years ended December 31, 2018, 2017 and 2016, these tax adjustments were $157.4 million, $203.8 million and $166.4 million, respectively, primarily related to foreign currency translation adjustments.

The cumulative foreign currency translation adjustments included translation loss of $172.9 million and translation gain of $22.1 million at December 31, 2018 and 2017, respectively, and which included losses of $111.8 million and $126.6 million, at December 31, 2018 and 2017, respectively, on loans designated as hedges of net investments.

Changes in AOCI by component for the years ended were as follows:


(in millions)	Foreign Currency Translation (Loss) Gain		(Loss) and Gain on Cash Flow Hedges		(Loss) and Gain on Net Investment Hedges		Net Unrealized Holding Gain on Available-for-Sale Securities		Pension Liability (Loss) Gain		Total

Balance, net of tax, at December 31, 2017	$	(104.5)	$	(12.6)	$	(127.6)	$	44.3	$	(90.6)	$	(291.0)
Other comprehensive (loss) income before reclassifications and tax impact	(160.1)		5.1		36.2		—		7.7		(111.1)
Tax expense	(20.1)		(1.6)		(20.0)		—		(4.7)		(46.4)
Other comprehensive (loss) income, net of tax, before reclassifications	(180.2)		3.5		16.2		—		3.0		(157.5)
Amounts reclassified from accumulated other comprehensive income, net of tax	—		9.7		—		(44.3)		4.4		(30.2)
Net (decrease) increase in other comprehensive income	(180.2)		13.2		16.2		(44.3)		7.4		(187.7)

Balance, net of tax, at December 31, 2018	$	(284.7)	$	0.6	$	(111.4)	$	—	$	(83.2)	$	(478.7)


(in millions)	Foreign Currency Translation (Loss) Gain		(Loss) and Gain on Cash Flow Hedges		(Loss) and Gain on Net Investment Hedges		Net Unrealized Holding Gain on Available-for-Sale Securities		Pension Liability (Loss) Gain		Total

Balance, net of tax, at December 31, 2016	$	(490.5)	$	(3.2)	$	(116.8)	$	—	$	(95.2)	$	(705.7)
Other comprehensive income (loss) before reclassifications and tax impact	354.6		(14.7)		(14.1)		45.0		(1.0)		369.8
Tax benefit (expense)	31.4		2.7		3.3		(0.7)		0.7		37.4
Other comprehensive income (loss), net of tax, before reclassifications	386.0		(12.0)		(10.8)		44.3		(0.3)		407.2
Amounts reclassified from accumulated other comprehensive income, net of tax	—		2.6		—		—		4.9		7.5
Net increase (decrease) in other comprehensive income	386.0		(9.4)		(10.8)		44.3		4.6		414.7

Balance, net of tax, at December 31, 2017	$	(104.5)	$	(12.6)	$	(127.6)	$	44.3	$	(90.6)	$	(291.0)

Reclassification out of accumulated other comprehensive loss for the years ended December 31 were as follows:



Details about AOCI Components	Amounts Reclassified from AOCI							Affected Line Item in the Consolidated Statements of Operations

(in millions)	2018		2017		2016




(Loss) gain on derivative financial instruments:
Interest rate swaps	$	(2.3)	$	(2.3)	$	(2.9)	Interest expense
Foreign exchange forward contracts	(8.9)		(3.0)		4.8		Cost of products sold
Foreign exchange forward contracts	—		—		0.1		SG&A expenses
Commodity contracts	—		—		(0.1)		Cost of products sold
Net (loss) gain before tax	(11.2)		(5.3)		1.9
Tax impact	1.5		2.7		(0.2)		Provision (benefit) for income taxes
Net (loss) gain after tax	$	(9.7)	$	(2.6)	$	1.7

Realized gain on available-for-sale securities:
Available -for-sale-securities	$	45.0	$	—	$	—	Other expense (income), net
Tax impact	(0.7)		—		—		Provision (benefit) for income taxes
Net gain after tax	$	44.3	$	—	$	—

Amortization of defined benefit pension and other postemployment benefit items:
Amortization of prior service benefits	$	0.2	$	0.2	$	0.2	(a)

Amortization of net actuarial losses	(6.3)		(7.0)		(5.3)		(a)
Net loss before tax	(6.1)		(6.8)		(5.1)
Tax impact	1.7		1.9		1.4		Provision (benefit) for income taxes
Net loss after tax	$	(4.4)	$	(4.9)	$	(3.7)

Total reclassifications for the period	$	30.2	$	(7.5)	$	(2.0)

(a) These accumulated other comprehensive income (loss) components are included in the computation of net periodic benefit cost for the years ended December 31, 2018, 2017, and 2016, respectively (see Note 15, Benefit Plans, for additional details).

BUSINESS COMBINATIONS

12 Months Ended

Dec. 31, 2018

Business Combinations [Abstract]

BUSINESS COMBINATIONS

Business Combinations

2018 Transactions

On May 1, 2018, the Company acquired all of the outstanding shares of privately held OraMetrix, Inc. for $120.0 million, with an additional payment totaling $30.0 million, subject to meeting earn-out provisions. OraMetrix specializes in orthodontic treatment planning software, wire bending, and clear aligner manufacturing and is headquartered in Richardson, Texas. At December 31, 2018, the Company recorded $58.0 million in goodwill related to the fair value of assets acquired and liabilities assumed and the consideration given for the acquisition. The purchase price has been assigned on the basis of the fair values of assets acquired and liabilities assumed. Goodwill is considered to represent the value associated with workforce and synergies the two companies anticipate realizing as a combined company. The goodwill is not expected to be deductible for tax purposes.

Intangible assets acquired consist of the following:


			Weighted Average
			Useful Life
(in millions, except for useful life)	Amount		(in years)

Customer relationships	$	18.3	15
Developed technology and patents	64.7		15
Tradenames and trademarks	13.5		Indefinite
Total	$	96.5

The results of operation for this business have been included in the accompanying financial statements as of the effective date of the transaction. The purchase price has been assigned on the basis of the fair values of assets acquired and liabilities assumed. This transaction was not material to the Company’s net sales and net loss attributable to Dentsply Sirona for the year ended December 31, 2018.

2017 Transactions

During the quarter ended June 30, 2017, the Company acquired RTD, a privately-held France-based manufacturer of endodontic posts for $132.0 million. At December 31, 2018, the Company recorded $83.9 million in goodwill related to the fair value of assets acquired and liabilities assumed and the consideration given for the acquisition. Goodwill is considered to represent the value associated with workforce and synergies the two companies anticipate realizing as a combined company. The goodwill is not expected to be deductible for tax purposes. Intangible assets acquired consist of the following:


			Weighted Average
			Useful Life
(in millions, except for useful life)	Amount		(in years)

Customer relationships	$	18.1	15
Developed technology and patents	22.4		15
Tradenames and trademarks	8.5		Indefinite
Total	$	49.0

2016 Transactions

On February 29, 2016, DENTSPLY merged with Sirona in an all-stock transaction and the registrant was renamed DENTSPLY SIRONA Inc. and the common stock continues to trade on the Nasdaq under the ticker “XRAY”. In connection with the Merger, each former share of Sirona common stock issued and outstanding immediately prior to February 29, 2016, was converted to 1.8142 shares of DENTSPLY common stock. The Company issued approximately 101.8 million shares of DENTSPLY common stock to former shareholders of Sirona common stock, representing approximately 42% of the approximately 242.2 million total shares of DENTSPLY common stock outstanding on the Merger date.

The following table summarizes the consideration transferred:


(in millions, except per share amount)*

Sirona common stock outstanding at February 29, 2016	56.1
Exchange ratio	1.8142
DENTSPLY common stock issued for consideration	101.8
DENTSPLY common stock per share price at February 26, 2016	$	60.67
Fair value of DENTSPLY common stock issued to Sirona shareholders			$	6,173.8
Fair value of vested portion of Sirona stock-based awards outstanding - 1.5 million
at February 29, 2016			82.4
Total acquisition consideration			$	6,256.2

*Lines may not add precisely to total due to rounding

Sirona contributed net sales of $1,220.2 million and operating loss of $1,543.1 million to the Company’s Consolidated Statements of Operations during the period January 1, 2017 to December 31, 2017. The operating loss includes a goodwill impairment charge of $1,650.9 million and an indefinite-lived intangible asset impairment charge of $346.7 million. Sirona contributed net sales of $1,039.9 million and operating income of $227.2 million to the Company's Consolidated Statements of Operations during the period from February 29, 2016 to December 31, 2016 which is primarily included in the Technologies & Equipment segment.

The following unaudited pro forma financial information reflects the consolidated results of operations of the Company had the Merger occurred on January 1, 2016. Sirona’s financial information has been compiled in a manner consistent with the accounting policies adopted by DENTSPLY. The following unaudited pro forma financial information for the year ended December 31, 2016, has been prepared for comparative purposes and does not purport to be indicative of what would have occurred had the Merger occurred on January 1, 2016, nor is it indicative of any future results.


	Pro forma - unaudited
	Year Ended
(in millions, except per share amount)	2016

Net sales	$	3,916.0
Net income attributable to Dentsply Sirona	$	437.0
Diluted earnings per common share	$	1.85

The pro forma financial information is based on the Company's preliminary assignment of consideration given and therefore subject to adjustment. These pro forma amounts were calculated after applying the Company’s accounting policies and adjusting Sirona’s results to reflect adjustments that are directly attributable to the Merger. These adjustments mainly include additional intangible asset amortization, depreciation, inventory fair value adjustments, transaction costs and taxes that would have been charged assuming the fair value adjustments had been applied from January 1, 2016, together with the consequential tax effects at the statutory rate. Pro forma results do not include any anticipated synergies or other benefits of the Merger.

For the year ended December 31, 2016, in connection with the Merger, the Company has incurred $29.9 million of transaction related costs, primarily amounts paid to third party advisers, legal and banking fees, which are included in Selling, general and administrative expenses in the Consolidated Statements of Operations.

In September 2016, the Company finalized the acquisitions of MIS Implants Technologies Ltd., a dental implant systems manufacturer headquartered in northern Israel and a small acquisition of a healthcare consumable business. Total purchase price related to these two acquisitions was $341.4 million, net of cash acquired of $66.9 million.

The results of operations for these businesses have been included in the accompanying financial statements as of the effective date of the respective transactions. The purchase prices have been assigned based on the fair values of assets acquired and liabilities assumed. These transactions (other than the Merger) were not material to the Company’s net sales and net income attributable to Dentsply Sirona for the year ended December 31, 2016.

Investment in Affiliates

On December 9, 2010, the Company purchased an initial ownership interest of 17% of the outstanding shares of DIO Corporation (“DIO”). In addition, on December 9, 2010, the Company invested $49.7 million in the corporate convertible bonds of DIO, which were permitted to be converted into common shares at any time. The bonds were designated by the Company as available-for-sale securities which are reported in, Prepaid expenses and other current assets, in the Consolidated Balance Sheets at December 31, 2014 and the changes in fair value were reported in AOCI. The contractual maturity of the bonds was December 2015. The Company had recorded the ownership in DIO under the equity method of accounting as it had significant influence over DIO.

In September 2015, the Company sold the bonds at face value. The Company recorded an unrealized holding loss, net of tax, of $4.8 million for the year ended December 31, 2016, in the Consolidated Statements of Comprehensive Income. As a result of sale of the bonds, the Company recorded $3.7 million, net of tax, of realized foreign currency gains in Other expense (income), net, in the Consolidated Statements of Operations for the year ended December 31, 2016. The fair value of the DIO bonds was $57.7 million at December 31, 2016 and a cumulative unrealized holding gain of $8.5 million was recorded in available-for-sale securities, net of tax in AOCI.

At December 31, 2016, the Company no longer has representation on the DIO Board of Directors and as a result the Company no longer has significant influence on the operations of DIO. In addition, the buyers of the convertible bonds exercised the conversion rights which resulted in DIO issuing additional shares and diluting the Company’s ownership position to 13%. As a result of these changes the Company used the cost-basis method of accounting for the remaining direct investment.

During the year ended December 31, 2017, the Company has reclassified the security as available-for-sale. At December 31, 2017 the fair value was $54.4 million, which is recorded in Prepaid expense and other current assets in the Consolidated Balance Sheets. The unrealized gain of $45.0 million was recorded in AOCI, net of tax, in the Consolidated Statements of Comprehensive Income. The book value of the Company’s direct investment in DIO was $9.4 million at December 31, 2017.

During the year ended December 31, 2018, the Company sold its direct investment in DIO. The gain was transferred out of AOCI and a gain of $44.1 million was recorded in Other expense (income), net in the Consolidated Statements of Operations.

SEGMENT AND GEOGRAPHIC INFORMATION

12 Months Ended

Dec. 31, 2018

Segment Reporting [Abstract]

SEGMENT AND GEOGRAPHIC INFORMATION

The operating businesses are combined into two operating groups, which generally have overlapping geographical presence, customer bases, distribution channels, and regulatory oversight.

These operating groups are considered the Company’s reportable segments as the Company’s chief operating decision-maker regularly reviews financial results at the operating group level and uses this information to manage the Company’s operations. The Company evaluates performance of the segments based on the groups’ net third party sales, excluding precious metal content, and segment adjusted operating income. The Company defines net third party sales excluding precious metal content as the Company’s net sales excluding the precious metal cost within the products sold, which is considered a measure not calculated in accordance with US GAAP, and is therefore considered a non-US GAAP measure. Management believes that the presentation of net sales, excluding precious metal content, provides useful information to investors because a portion of Dentsply Sirona’s net sales is comprised of sales of precious metals generated through sales of the Company’s precious metal dental alloy products, which are used by third parties to construct crown and bridge materials. Due to the fluctuations of precious metal prices and because the cost of the precious metal content of the Company’s sales is largely passed through to customers and has minimal effect on earnings, Dentsply Sirona reports net sales both with and without precious metal content to show the Company’s performance independent of precious metal price volatility and to enhance comparability of performance between periods. The Company uses its cost of precious metal purchased as a proxy for the precious metal content of sales, as the precious metal content of sales is not separately tracked and invoiced to customers. The Company believes that it is reasonable to use the cost of precious metal content purchased in this manner since precious metal dental alloy sale prices are typically adjusted when the prices of underlying precious metals change. The Company’s exclusion of precious metal content in the measurement of net third party sales enhances comparability of performance between periods as it excludes the fluctuating market prices of the precious metal content. The Company also evaluates segment performance based on each segment’s adjusted operating income before provision for income taxes and interest. Segment adjusted operating income is defined as operating income before income taxes and before certain corporate headquarter unallocated costs, restructuring and other costs, interest expense, interest income, other expense (income), net, amortization of intangible assets and depreciation resulting from the fair value step-up of property, plant and equipment from acquisitions. The Company’s segment adjusted operating income is considered a non-US GAAP measure. A description of the products and services provided within each of the Company’s two operating segments is provided below.

Technologies & Equipment

This segment includes responsibility for the worldwide design, manufacture, sales and distribution of the Company’s Dental Technology and Equipment Products and Healthcare Consumable Products. These products includes dental implants, laboratory dental products, CAD/CAM systems, imaging systems, treatment centers as well as consumable medical device products.

Consumables

This segment is responsible for the worldwide design, manufacture, sales and distribution of the Company’s Dental Consumable Products which include preventive, restorative, instruments, endodontic, and orthodontic dental products.

Reclassification of Prior Years Amounts

Certain reclassifications have been made to prior years' data in order to conform to a current year presentation.

The following table sets forth information about the Company’s segments for the years ended December 31:


Third Party Net Sales
(in millions)	2018		2017		2016

Technologies & Equipment	$	2,135.6	$	2,200.8	$	2,050.5
Consumables	1,850.7		1,792.6		1,694.8


Total net sales	$	3,986.3	$	3,993.4	$	3,745.3


Third Party Net Sales, Excluding Precious Metal Content
(in millions)	2018		2017		2016

Technologies & Equipment	$	2,098.4	$	2,160.3	$	1,986.4
Consumables	1,850.7		1,792.6		1,694.6


Total net sales, excluding precious metal content	$	3,949.1	$	3,952.9	$	3,681.0
Precious metal content of sales	37.2		40.5		64.3
Total net sales, including precious metal content	$	3,986.3	$	3,993.4	$	3,745.3


Depreciation and Amortization
(in millions)	2018		2017		2016

Technologies & Equipment	$	269.3	$	257.5	$	218.1
Consumables	59.9		57.5		52.6

All Other (a)	1.6		1.4		1.0
Total	$	330.8	$	316.4	$	271.7

(a) Includes amounts recorded at Corporate headquarters.


Segment Operating Income (Loss)
(in millions)	2018		2017		2016

Technologies & Equipment	$	255.6	$	412.6	$	355.7
Consumables	495.8		493.0		445.3

Segment adjusted operating income before income taxes and interest	$	751.4	$	905.6	$	801.0

Reconciling Items (income) expense:
All Other (a)	197.6		196.5		162.8
Restructuring and other costs	221.0		425.2		23.2
Goodwill Impairment	1,085.8		1,650.9		—
Interest expense	37.3		38.3		35.9
Interest income	(2.1)		(2.4)		(2.0)
Other expense (income), net	(34.9)		5.3		(20.1)
Amortization of intangible assets	197.9		189.1		155.3
Depreciation resulting from the fair value step-up of property, plant and equipment from business combinations	7.2		6.2		5.0
(Loss) income before income taxes	$	(958.4)	$	(1,603.5)	$	440.9

(a) Includes results of Corporate headquarters, inter-segment eliminations and one distribution warehouse not managed by named segments.


Capital Expenditures
(in millions)	2018		2017		2016

Technologies & Equipment	$	118.0	$	98.6	$	73.7
Consumables	50.9		37.6		42.2

All Other (a)	13.6		8.1		9.1
Total	$	182.5	$	144.3	$	125.0

(a) Includes capital expenditures of Corporate headquarters.


Assets
(in millions)	2018		2017

Technologies & Equipment	$	6,380.2	$	8,130.6
Consumables	2,158.4		1,965.1

All Other (a)	148.4		278.8
Total	$	8,687.0	$	10,374.5

(a) Includes results of Corporate headquarters, inter-segment eliminations and one distribution warehouse not managed by named segments.

Geographic Information

The following table sets forth information about the Company’s operations in different geographic areas for the years ended December 31, 2018, 2017 and 2016. Net sales reported below represent revenues for shipments made by operating businesses located in the country or territory identified, including export sales. Property, plant and equipment, net, represents those long-lived assets held by the operating businesses located in the respective geographic areas.


(in millions)	United States		Germany		Sweden		Other Foreign		Consolidated

2018
Net sales	$	1,269.9	$	494.3	$	55.2	$	2,166.9	$	3,986.3
Property, plant and equipment, net	211.1		339.3		99.3		220.9		870.6

2017
Net sales	$	1,376.5	$	493.3	$	52.4	$	2,071.2	$	3,993.4
Property, plant and equipment, net	202.0		331.5		103.4		239.1		876.0

2016
Net sales	$	1,383.0	$	617.0	$	53.2	$	1,692.1	$	3,745.3
Property, plant and equipment, net	192.5		244.1		82.5		280.7		799.8

Product and Customer Information

The following table presents net sales by product category for the years ended December 31:


(in millions)	2018		2017		2016

Dental consumables products	$	1,829.3	$	1,769.7	$	1,770.3
Dental technology and equipment products	1,808.2		1,895.7		1658.6
Healthcare consumable products	348.8		328.0		316.4


Total net sales	$	3,986.3	$	3,993.4	$	3,745.3

Dental Consumable Products

Dental consumable products consist of value added dental supplies and small equipment used in dental offices for the treatment of patients. It also includes specialized treatment products used within the dental office and laboratory settings including products used in the preparation of dental appliances by dental laboratories.

Dentsply Sirona’s dental supplies include endodontic (root canal) instruments and materials, dental anesthetics, prophylaxis paste, dental sealants, impression materials, restorative materials, tooth whiteners and topical fluoride. Small equipment products include dental handpieces, intraoral curing light systems, dental diagnostic systems and ultrasonic scalers and polishers.

The Company’s products used in the dental laboratories include dental prosthetics, including artificial teeth, precious metal dental alloys, dental ceramics and crown and bridge materials. Dental laboratory equipment products include amalgamators, mixing machines and porcelain furnaces.